Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Total Non-Current Liabilities (2017 - 2025)

Iovance Biotherapeutics has reported Total Non-Current Liabilities over the past 8 years, most recently at $76.2 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $76.2 million for Q4 2025, down 1.87% from a year ago — trailing twelve months through Dec 2025 was $76.2 million (down 1.87% YoY), and the annual figure for FY2025 was $76.2 million, down 1.87%.
  • Total Non-Current Liabilities for Q4 2025 was $76.2 million at Iovance Biotherapeutics, down from $76.9 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for IOVA hit a ceiling of $106.6 million in Q1 2024 and a floor of $70.6 million in Q1 2023.
  • Median Total Non-Current Liabilities over the past 3 years was $78.7 million (2024), compared with a mean of $82.7 million.
  • Biggest five-year swings in Total Non-Current Liabilities: soared 50.95% in 2024 and later fell 28.53% in 2025.
  • Iovance Biotherapeutics' Total Non-Current Liabilities stood at $85.4 million in 2023, then decreased by 9.07% to $77.7 million in 2024, then dropped by 1.87% to $76.2 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $76.2 million (Q4 2025), $76.9 million (Q3 2025), and $79.8 million (Q2 2025) per Business Quant data.